Stocks and Investing
Stocks and Investing
Thu, October 11, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joel Beatty Maintained (SNDX) at Strong Buy with Decreased Target to $12 on, Oct 11th, 2018
Joel Beatty of Citigroup, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Decreased Target from $15 to $12 on, Oct 11th, 2018.
Joel has made no other calls on SNDX in the last 4 months.
There is 1 other peer that has a rating on SNDX. Out of the 1 peers that are also analyzing SNDX, 0 agree with Joel's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joel
- Edward White of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $30 on, Thursday, July 12th, 2018